P21-dependent g(1)arrest with downregulation of cyclin D1 and upregulation of cyclin E by the histone deacetylase inhibitor FR901228 - Wikidata - wikimedia - TriplyDB

P21-dependent g(1)arrest with downregulation of cyclin D1 and upregulation of cyclin E by the histone deacetylase inhibitor FR901228

P21-dependent g(1)arrest with downregulation of cyclin D1 and upregulation of cyclin E by the histone deacetylase inhibitor FR901228

http://www.wikidata.org/entity/Q36621938

about

New insights into the role of nuclear factor-kB in cell growth regulation Cutaneous T-cell lymphoma: 2014 update on diagnosis, risk-stratification, and management Histone Deacetylase Inhibitor Romidepsin Has Differential Activity in Core Binding Factor Acute Myeloid Leukemia Epigenetic influences on sensory regeneration: histone deacetylases regulate supporting cell proliferation in the avian utricle.Update on the treatment of cutaneous T-cell lymphoma (CTCL): Focus on vorinostat.Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma Romidepsin: a new therapy for cutaneous T-cell lymphoma and a potential therapy for solid tumors.Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma.Pharmacology of epigenetics in brain disorders Laboratory correlates for a phase II trial of romidepsin in cutaneous and peripheral T-cell lymphoma Histone deacetylase inhibitors: molecular mechanisms of action and clinical trials as anti-cancer drugs.Histone deacetylase: a potential therapeutic target for fibrotic disorders Histone modification enzymes: novel targets for cancer drugs.Targeting histone deacetyalses in the treatment of B- and T-cell malignancies.Histone deacetylase inhibitors in the treatment of hematological malignancies and solid tumors.Chemotherapeutic effect of calcidiol derivative B3CD in a neuroblastoma xenograft model.Phase II trial of romidepsin (NSC-630176) in previously treated colorectal cancer patients with advanced disease: a Southwest Oncology Group study (S0336)New strategies in peripheral T-cell lymphoma: understanding tumor biology and developing novel therapies Interpreting clinical assays for histone deacetylase inhibitors.Augmenting antitumor immune responses with epigenetic modifying agents.Signal transduction mediated by the Ras/Raf/MEK/ERK pathway from cytokine receptors to transcription factors: potential targeting for therapeutic intervention.Romidepsin (Istodax, NSC 630176, FR901228, FK228, depsipeptide): a natural product recently approved for cutaneous T-cell lymphoma Histone deacetylase inhibitors: emerging mechanisms of resistance.Epigenetics in prostate cancer.STAT-3 overexpression and p21 up-regulation accompany impaired regeneration of fatty livers.Cutaneous T-cell lymphoma: a paradigm for biological therapies.The synergic effect of vincristine and vorinostat in leukemia in vitro and in vivo.Characterization of a gene cluster responsible for the biosynthesis of anticancer agent FK228 in Chromobacterium violaceum No. 968 Vorinostat-An Overview.Targeting paediatric acute lymphoblastic leukaemia: novel therapies currently in development Novel therapeutic agents for cutaneous T-Cell lymphoma.Differential effects of histone deacetylase inhibitors in tumor and normal cells-what is the toxicological relevance?Histone deacetylase inhibitor-mediated cell death is distinct from its global effect on chromatin.RA-XII inhibits tumour growth and metastasis in breast tumour-bearing mice via reducing cell adhesion and invasion and promoting matrix degradation.Cutaneous T-cell lymphoma: 2016 update on diagnosis, risk-stratification, and management.Susan Bates, M.D., and Antonio "Tito" Fojo, M.D., Ph.D.: Thirty Years of Research, Discovery, Service, and Mentorship at the National Cancer Institute.Suppressive oligodeoxynucleotides synergistically enhance antiproliferative effects of anticancer drugs in A549 human lung cancer cells Histone deacetylase inhibitors (HDACIs): multitargeted anticancer agents A coumarin derivative (RKS262) inhibits cell-cycle progression, causes pro-apoptotic signaling and cytotoxicity in ovarian cancer cells.Development of histone deacetylase inhibitors for cancer treatment.

P2860

Q26058119-C498A548-2ACF-4979-A0A3-E5452EE580EE Q27024076-8A00901F-1D5D-47F8-9D8F-D38E9A75390D Q29394054-5B48A1CB-CA05-4EEB-8C1B-BD602385AA2E Q30432406-71C600B7-8E28-42D9-A616-7930698E83E8 Q33385966-F5783331-E2C0-47BC-B24A-06CE8A87D0C6 Q33386623-B0F9DE4D-2ECF-4A51-880C-CB37EAB5BF08 Q33390876-440999F3-C28E-4DAA-AFC8-0508D18615FB Q33394324-6D603C3D-3BF6-4C3E-88F1-EAAB8FD13771 Q33673025-2508EF34-7DC2-416F-BD5C-1C898E7192D9 Q33726989-1EAD0FA6-F3FC-4667-8BA1-D826AD91470F Q34171631-46B1CA00-FFEA-4D79-A165-A8097AA17B4E Q34257607-115B72FA-5B8E-4B89-8388-DA10B71E4A06 Q34322087-FB2CB2E0-210F-4960-B9AD-C843080760BA Q34414452-A6F5EC05-549B-4AB5-83B7-875B88B3D93C Q34416994-B59DB632-1B9F-48D0-94AC-7281241C7380 Q34505680-D1CA09AF-A975-4D8D-8952-9BEE1BC276D5 Q34510205-7EAE290A-D611-4959-8EAF-0BADE50642E0 Q34683488-90DCDA54-767D-4330-9A06-74BE787BD517 Q35003657-712B762E-8DF3-4BD6-BCF9-318A2FBA6C47 Q35048054-D6012873-BA33-4B9E-9B75-ED8FEC73FC33 Q35166852-17B0E8BF-7FE1-4CA9-8069-BA8C853DE1DD Q35186682-E26EDEFA-0CDF-4996-9AAE-6411D8A1C297 Q35592607-9E52E8CF-AF0E-43CF-A7BA-86935F5B908C Q35608952-A1E798DC-B42F-463A-95E7-512E1D4C99B7 Q35747457-9BDB11F5-C579-4645-ADE0-62D438D6301D Q35821012-7BAC2C7B-5B75-4343-81E7-CACCAAFA8CCA Q35856765-087BA2F9-0E4E-457D-AF0F-E511840AFAB3 Q35913058-E4FAE9C0-7CAD-4C89-B919-99B6899F2E27 Q35944176-F7B90FEE-B819-4B4E-9306-D832711B6AA1 Q35967452-5BA6CDB5-F396-491A-B555-1CAC2F6D9219 Q36161365-6FE2A92E-B06B-4C6A-BC82-585F16F39053 Q36179533-1B1FEA71-C04F-4886-8F8A-7A36F29625B4 Q36283075-DF9A4215-C4CB-4ED1-B75D-7EFCFC4840E2 Q36305387-13DC6BC2-9A73-44C9-9BC2-CBC8AB1C2A1E Q36470196-D23B3F53-CCC1-40B4-9F5C-31DB5993A5F8 Q36478750-0E618099-1533-479C-9AF3-C81FFC3D30D7 Q36643420-646F8B45-3E79-4568-AA00-2FAC643D95D1 Q36645808-587DD135-BF6E-499A-971E-739CF64FA7B4 Q36711125-73DAD4C7-B848-421F-9F78-88170E4ACD26 Q36788512-5A512937-7C6C-4CEA-B0A8-5C75DC8E0FFC

P2860

P21-dependent g(1)arrest with downregulation of cyclin D1 and upregulation of cyclin E by the histone deacetylase inhibitor FR901228

http://www.wikidata.org/entity/Q36621938

description

2000 nî lūn-bûn

@nan

2000年の論文

@ja

2000年論文

@yue

2000年論文

@zh-hant

2000年論文

@zh-hk

2000年論文

@zh-mo

2000年論文

@zh-tw

2000年论文

@wuu

2000年论文

@zh

2000年论文

@zh-cn

name

P21-dependent g(1)arrest with ...... deacetylase inhibitor FR901228

@ast

P21-dependent g(1)arrest with ...... deacetylase inhibitor FR901228

@en

type

label

P21-dependent g(1)arrest with ...... deacetylase inhibitor FR901228

@ast

P21-dependent g(1)arrest with ...... deacetylase inhibitor FR901228

@en

prefLabel

P21-dependent g(1)arrest with ...... deacetylase inhibitor FR901228

@ast

P21-dependent g(1)arrest with ...... deacetylase inhibitor FR901228

@en

P1433

Q36621938-7CC5A615-0CFC-44EB-B89F-96D29034EB81

P1476

Q36621938-241700FE-C099-45B7-B1D2-557464A69C20

P2093

Q36621938-4B54614D-A18E-4B15-83A2-10B79DE2AA69

Q36621938-8A3EBFAB-3670-43E7-9943-B26679719CD0

Q36621938-996E8CA9-AA2D-44CA-9B7B-32BE49F594B0

Q36621938-BA87163E-E513-4DFD-9689-957F45364E84

Q36621938-BB43530C-849B-4999-B301-56E2BD1ED3EF

Q36621938-C8819C25-93BE-44D8-8466-0471D770F979

Q36621938-EDB88391-8FF2-4A99-879F-B25C5883801C

P2860

Q36621938-06FC2F48-A152-42F2-93F2-6EEA50264764

Q36621938-10B62C1D-5C33-48FE-BDC7-50D48162C8BB

Q36621938-121C7A8C-E52B-4B62-AE77-59D75C0D2F92

Q36621938-1A82E6D8-CFEB-4AE0-AB90-C9B54093AAC8

Q36621938-26491BD2-3763-41A5-9C92-651EBCE9B00C

Q36621938-30651068-241B-412F-9A79-6C978CF01203

Q36621938-38BE7208-1D34-48D4-92E6-7F4A7E0DC738

Q36621938-3B74318B-02D0-4E7E-B84C-3C09D07A89A5

Q36621938-3C33ACC9-E936-4A85-91FA-E109C9C717C8

Q36621938-3FD17135-3A88-4E0C-BCA2-9AF185948565

P2888

Q36621938-55806904-F5B5-4DC8-A1FE-BC2603D7D2B7

P304

Q36621938-16603863-89B3-4D1F-ACA3-FBC084F29736

P31

Q36621938-5B5BCA7C-4AC5-431C-A366-E0625387D729

P356

Q36621938-82966C6F-4A21-4ED3-AF83-475A187597C4

P407

Q36621938-622C56A7-DD57-45B0-AE3F-1A9EA4EA58EA

P433

Q36621938-8B4BE565-D1FA-49F9-9549-C0DF2B8421CE

P478

Q36621938-21E84F62-A9C7-4D71-9CEC-5920614BDB88

P577

Q36621938-52C8722C-6A2D-4355-B39F-D6D78219AB37

P5875

Q36621938-782815C7-D95E-45CC-A1CC-D2BE6231D802

P6179

Q36621938-05FFDBBA-BC1E-45C5-8662-8F6E7CDAA50B

P698

Q36621938-E3B8DF3E-F473-4386-8B18-88A06E2558BE

P932

Q36621938-9DA4F46E-669A-4AB5-BEB5-7E87205F0B8E

P356

P1433

British Journal of Cancer

P1476

P21-dependent g(1)arrest with ...... deacetylase inhibitor FR901228

@en

P2093

Bates SE

http://www.w3.org/2001/XMLSchema#string

Blagosklonny MV

http://www.w3.org/2001/XMLSchema#string

Mertins S

http://www.w3.org/2001/XMLSchema#string

Sackett D

http://www.w3.org/2001/XMLSchema#string

Sandor V

http://www.w3.org/2001/XMLSchema#string

Sausville E

http://www.w3.org/2001/XMLSchema#string

Senderowicz A

http://www.w3.org/2001/XMLSchema#string

P2860

A restriction point for control of normal animal cell proliferation

The retinoblastoma protein and cell cycle control

WAF1, a potential mediator of p53 tumor suppression

Retinoblastoma protein recruits histone deacetylase to repress transcription

Retinoblastoma protein represses transcription by recruiting a histone deacetylase

Role of the histone deacetylase complex in acute promyelocytic leukaemia

Rb interacts with histone deacetylase to repress transcription

p21 is necessary for the p53-mediated G1 arrest in human cancer cells

Requirement for p53 and p21 to sustain G2 arrest after DNA damage

Cancer cell cycles

P2888

P304

817-825

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1054/BJOC.2000.1327

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

83

http://www.w3.org/2001/XMLSchema#string

P577

2000-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

12367769

http://www.w3.org/2001/XMLSchema#string

P6179

1013175016

http://www.w3.org/2001/XMLSchema#string

P698

10952788

http://www.w3.org/2001/XMLSchema#string

P932

2363539

http://www.w3.org/2001/XMLSchema#string